InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow INM
InMed Pharmaceuticals Inc. (INM) EV/Sales
As of 16 October 2026, InMed Pharmaceuticals Inc. (INM) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −5.6× (December 2022) to 1.0× (July 2026); the current reading is higher than 96% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.2× | — |
| FY2024 | −0.9× | — |
| FY2023 | −1.6× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −0.5× | — |
| Sep 2025 | −0.1× | — |
| Jun 2025 | −1.2× | — |
| Mar 2025 | −0.4× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. compare | 0.0× |
| GELS Gelteq Limited compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| YCBD cbdMD, Inc. compare | 0.2× |
| BFRI Biofrontera Inc. compare | 0.2× |
| INM InMed Pharmaceuticals Inc. | 0.6× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)